Fusion proteins are essential for advancing therapeutic innovations but present significant analytical challenges due to molecular complexity, such as diverse glycosylation patterns.
This diversity, combined with multiple charge states during electrospray ionization, complicates intact mass analysis. A high-resolution mass analyzer is essential to deconvolute this complexity and produce accurate spectra for effective characterization.
This application note demonstrates how advanced LC-MS techniques provide comprehensive fusion protein characterization. It highlights innovative approaches to detect glycoforms, confirm glycosylation patterns and identify subtle sequence variants, even in highly complex systems.
Download this application note to discover:
- Cutting-edge methods for fusion protein analysis under native and denaturing conditions
- Advanced strategies to resolve glycoforms and confirm glycosylation patterns
- Techniques for detecting sequence variants with precision
Keywords:
maXis II,
Fusion protein,
Glycosylation, Data
Analysis software,
Dissect
Characterization of a fusion protein
under native and denaturing
conditions with maXis II
Authors: Anjali Alving
Bruker Daltonics, Billerica, MA
Abstract
The maXis II UHR-QTOF was used
to characterize key attributes of a
fusion protein in its native conformation as well as under denaturing
conditions. The maXis II high resolving power enabled the detection of
the various glycoforms on the protein monomer and confirmed that
the same glycosylation pattern was
present on the fusion protein dimer.
Additionally a sequence variant
expressed by only one of two clones
was detected by the denaturing
method despite a mass difference
of only 8 Da.
Introduction
Fusion proteins, the genetic combination of two or more originally
separate proteins, are highly successful biopharmaceuticals and
can offer a combination of attributes that enhance their ability to
treat disease. They are often used
in the context of bio-betters, providing
improved pharmacokinetic and pharmacodynamic values to the original
therapeutic.
One challenge encountered when
developing a fusion protein can be
additional molecular complexity. While
glycosylation is usually straightforward
to assess on a recombinant antibody,
fusion proteins may contain a large
number of N- and O-glycosylation
sites. This creates a significant challenge for intact mass analysis of the
protein by electrospray ionization, as
the potentially hundreds to thousands
of glycoforms present are further convoluted by the multiple charge states
of ions created. A high resolution mass
analyzer is therefore essential to successfully generate a deconvoluted
spectrum for such proteins.
Here we utilize the maXis II UHR ESI
QTOF mass spectrometer (Bruker Daltonics, Billerica, MA) to characterize a
fusion protein in denaturing and native
conditions to determine the glycosylation mass profile of its monomer and
non-covalent dimer forms, respectively. Additionally the high resolution
Figure 2: Fusion Protein Dimer by Native Spray MS – Confirmation of expected glycosylation pattern
Figure 1: Fusion protein monomer - Maximum Entropy Deconvolution and SNAP II peak
picking shows monoisotopic mass
5 Intens - x10
81500 82000 82500 83000 83500 84000 84500 85000 85500 m/z
2.0
1.5
1.0
0.5
0.0
81476.3701
81932.1940
82094.0191
82256.4525
82418.9596
82750.9529
82913.5580
83075.4955
83244.2633
83569.4217
83732.8672
83899.3476
84064.0553
84226.6017
84390.8781
84556.5204 84882.7993
85049.3088
85211.7106
85377.0626
85710.4777
85870.1963
Hexose
Hexose
Hexose
Hexose
Hexose
Hexose Hexose
Hexose
Hexose
Hexose
Hexose
Hexose
Hexose Hexose
Hexose
HexNAcHexNeuAc HexNAcHexNeuAc HexNAcHexNeuAc HexNAcHexNeuAc
HexNAcHex2NeuAc HexNAcHex2NeuAc
HexNAcHex2NeuAc HexNAcHex2NeuAc
40500 41000 41500 42000 42500 43000 43500 m/z
Intens.
x 105
0.00
Mr
'41596.4992
Mr
'41920.6027
0.25
0.50
0.75
1.00
1.25 Mr
'41759.5564
Mr
'40940.2785
Mr
'41102.3287
Mr
'41264.3709 Mr
'42211.7020 Mr
'42502.8106
Mr
'43071.0137
Mr
'43233.0683 Mr
'43525.1611
41560 41580 41600 41620 41640 41660m/z
Intens.
x 105
1.5
1.0
0.5
0.0
Mr
'41596.4992
Mr
'41556.4806
Mr
'41618.4702 Mr
'41633.4534
of the maXis II enabled the detection
of a sequence variant of 8 Da on a
second fusion protein produced from
one of two different clones. The dissect command in Data AnalysisTM
software (Bruker Daltonics, Billerica,
MA) was used to automatically find
compounds on an LC-MS chromatogram trace; this algorithm is based on
the principle that all ions that have the
maximum intensity at the same time
belong to the same compound, thus
making it possible to find distinct compounds even if the peaks almost completely overlap.
Experimental
Test Materials and Instrumentation
Samples from two fusion protein
bio-therapeutic programs (here titled
BMS Protein 1 and BMS Protein
2) were provided by Bristol-Myers
Squibb (Hopewell, NJ). Samples of
BMS Protein 1 were evaluated using
native spray analysis, and BMS Protein
2 for sequence variant determination.
The workflow included the maXis II
UHR-QTOF and Data Analysis software (Bruker Daltonics, Billerica, MA),
and UltimateTM 3000 RSLC (Thermo
Scientific, San Jose, CA).
Results and Discussion
LC-MS of Fusion Protein Monomer
in Denaturing Conditions
The non-covalent dimer of the fusion
protein BMS Protein 1 was first analyzed under denaturing LC-MS conditions with an Acquity UPLC BEH C4,
2.1 x 100 mm column (Waters, Milford, MA). The mobile phases were
water + 0.1 % formic acid + 0.05 %
TFA and acetonitrile + 0.1 % formic
acid + 0.05 % TFA with a 30 min gradient at a flow rate of 0.3 ml/min. The
high resolving power of the maXis II
enabled the isotopic resolution of the
fusion protein while maintaining the
True Isotopic PatternTM (TIP) of isotope spacing and intensity under fast
HPLC conditions. This enables protein
modifications to be easily determined
and accurately quantified. The SNAP
II peak picking algorithm was used
to determine the monoisotopic mass
of the fusion protein glycoforms with
high mass accuracy (Figure 1).
The observed delta-masses on the
fusion protein mass spectrum were
consistent with the expected predominant O-glycoforms, as shown in Table
1.
LC-MS of Fusion Protein Dimer in
Native Conditions
Analysis of the non-covalent fusion
protein dimer BMS Protein 1 was carried out under native conditions. After
Figure 3: Separation of a sequence variant of the fusion protein seen as peak # 2
Figure 4: Mass spectra of the mutant protein in peak #2 showing a -8 Da mass shift
Intens - x10 7
6
4
2
0
5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0
2
TIC 1
41360 41380 41400 41420 41440 41460 41480 m/z
Intens.
x 105
6
x 104
4
2
0
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Fusion protein B_BEH_C4_RA3_01_317.d: +MS, 9.9-10.3min, Deconvoluted (MaxEnt, 1210.18-1993.53, *0.125, 55000)
Fusion protein B_BEH_C4_RA3_01_317.d: +MS, 10.4-10.7min, Deconvoluted (MaxEnt, 1195.27-1997.17, *0.125, 55000)
Mr
'41395.46
Mr
'41392.43
Mr
'41336.42
Mr
'41418.43 Mr
'41437.43
Mr
'41415.40 Mr
'41434.37 Mr
'41457.38
Peak 1: 99 - 10.3 min
Peak 2: 10.4 - 10.7 min
- 8 Da shift in shoulder peak
Mr
'41380.43
Mr
'41372.39
Time
[min]
a buffer exchange into 10 mM ammonium bicarbonate using a molecular
weight cut off (30 kDa) spin filter, 15.6
µg of the fusion protein was loaded on
a Polyhydroxyethyl A 3 µm, 1 x 50 mm
column (PolyLC Inc., Columbia, MD)
and eluted under isocratic conditions
with 100 mM ammonium at a flow rate
of 15 µl/min for 10 min. Native Spray
of the intact fusion protein allowed the
visualization of the non-covalent fusion
protein dimer (Figure 2). The glycosylation pattern was consistent with the
glycans observed on the monomer of
the fusion protein (Figure 1).
Sequence Variant Determination
A second fusion protein, BMS Protein 2, was expressed from a clone
containing a sequence variant with an
abundance of ~20%. This variant corresponded to a mass shift of 8 Da.
In order to detect the sequence variant, the fusion protein samples were
analyzed by LC-MS under denaturing
conditions as described above, and
the resulting spectra were analyzed
using Data Analysis. Figure 3 shows
the chromatographic separation of a
sequence variant (peak # 1) from the
expected protein (peak # 2). An examination of the mass spectra corresponding to the two chromatographic
peaks revealed a -8 Da mass shift in
the small peak # 2 (Figure 4).
Data AnalysisTM Software and
Dissect
Figure 5 illustrates the Dissect algorithm that is used for compound
detection in an LC-MS chromatogram
even if the peaks completely overlap.
Four compounds were identified by
the Dissect software and their corresponding mass spectra seen in Figure
6 shows distinctly different species
which include spectra under the main
peak and lower intensity heterogeneities eluting under the overlapping
compounds.
The Dissect algorithm utilizes fuzzylogic algorithms, which allow a peak
separation process to be run without
the need for user interaction or any
prior information. The Dissect algorithm makes it possible to separate
overlapping peaks even if their retention times differ by half the scan time
and their intensities differ by more
than one order of magnitude.
Figure 5: Dissect detection of co-eluting compounds
Figure 6: Deconvoluted mass spectra of Dissect detected compounds
The Compounds - Dissect command is used to automatically find
compounds on an LC-MS chromatogram trace even if the peaks almost
completely overlap
Intens - x10
6
9.8 10.0 10.2 10.4 10.6 10.8 11.0 11.2Time[min]
5
4
3
2
1
0
41000 41250 41500 41750 42000 42250 42500 42750 m/z
Intens.
x 106
1.00
Mr '41395.4674
Mr '41234.4161
Mr '41073.3668 Mr '41687.5627 Mr '41890.6549
Mr '42051.6910
Mr '41386.4372
Mr '41686.5554
Mr '41977.6491 Mr '42342.7847
Mr '41426.4299 Mr '41676.5302
Mr '41975.6411
Mr '42267.7332
Mr '42632.8693
Mr '41391.4273 Mr '41684.5199
Mr '41979.6350
Mr '42342.7450
Mr '42638.8466
0.75
0.50
0.25
0.00 x105
3
2
1
x105 0
0.8
0.6
0.4
0.2
0.0 x104
2.0
1.5
1.0
0.5
0.0
Conclusions
• The maXis II UHR ESI QTOF mass spectrometer was used to obtain isotopic resolution of the 40 kDa monomer
of a highly glycosylated fusion protein. The SNAP II peak picking algorithm calculated the monoisotopic
molecular weight from isotopically resolved peaks with high isotopic fidelity (True Isotopic Pattern TM)
• Native spray data of the 80 kDa non-covalent fusion protein dimer confirmed the expected glycosylation pattern
• The maXis II UHR ESI QTOF mass spectrometer was also able to detect a sequence variant corresponding to a
-8 Da mass shift that was present at ~20% abundance.
• The Dissect software enabled identification of 4 distinctly different species despite overlapping peaks in the
chromatogram.
Acknowledgments
We would like to thank Dr. Thomas Slaney (Bristol Myers Squibb, Hopewell, NJ) for providing the samples for this study and
his insights and comments in writing this application note.
Glycan
Monoisotopic
Mass (Da)
Elemental
Composition
Hexose
HexNAc-Hex-NeuAc
HexNAc-Hex-2xNeuAc
162.05282
656.22761
947.32303
C6H10O5
C25H40N2O18
C36H57N3O26
Table 1. Expected glycosylation on fusion protein
For research use only. Not for use in diagnostic procedures.
ms.sales.bdal@bruker.com - www.bruker.com
Learn More
Bruker Daltonics is continually improving its products and reserves the right
to change specifications without notice. © Bruker Daltonics 05-2018, LCMS-142, 1860650, Rev. 01
Are you looking for further Information? Check out the Link or scan
the QR Code.
www.bruker.com/maxis-II
Bruker Daltonics GmbH & Co. KG
Bremen · Germany
Phone +49 (0)421-2205-0
Bruker Scientific LLC
Billerica, MA · USA
Phone +1 (978) 663-3660